Table 2:
Risk factors of graft rejection
| No Rejection (n=40) | Rejection (n=29) | p | |
|---|---|---|---|
| Age at ICI initiation, yr | 65.5 (54.3–72.5) | 63 (54–70) | 0.596 |
| Female, n (%) | 8 (20.0) | 3 (10.3) | 0.336 |
| Transplant type, n (%) | 0.014 | ||
| LUKTx | 6 (15.0) | 10 (34.5) | |
| LRKTx | 13 (32.5) | 11 (37.9) | |
| DDKTx | 21 (52.5) | 6 (20.7) | |
| Unknown | 0 (0.0) | 2 (6.9) | |
| HLA antigen mismatch, n (%) | 0.425 | ||
| 0 | 5 (12.5) | 1 (3.4) | |
| 1 | 2 (5.0) | 0 (0.0) | |
| 2 | 3 (7.5) | 3 (10.3) | |
| 3 | 9 (22.5) | 7 (24.1) | |
| 4 | 3 (7.5) | 1 (3.4) | |
| 5 | 7 (17.5) | 3 (10.3) | |
| 6 | 1 (2.5) | 0 (0.0) | |
| Unknown | 10 (25.0) | 14 (48.3) | |
| DSA, n (%) | 5 (12.5) | 6 (20.7) | 0.319 |
| Cancer type, n (%) | 0.430 | ||
| cSCC | 15 (37.5) | 9 (31.0) | |
| Melanoma | 10 (25.0) | 12 (41.4) | |
| NSCLC | 4 (10.0) | 4 (13.8) | |
| Merkel Cell Carcinoma | 4 (10.0) | 0 (0.0) | |
| RCC | 2 (5.0) | 1 (3.4) | |
| Bladder | 2 (5.0) | 0 (0.0) | |
| Others | 3 (7.5) | 3 (10.3) | |
| Number of immunosuppressants, n (%) | 0.069 | ||
| 0 | 0 (0.0) | 1 (3.4) | |
| 1 | 8 (20.0) | 12 (41.4) | |
| 2 | 21 (52.5) | 13 (44.8) | |
| 3 | 11 (27.5) | 3 (10.3) | |
| Immunosuppression agents | |||
| Steroid, n (%) | 35 (87.5) | 24 (82.8) | 0.837 |
| Antimetabolite, n (%) | 12 (30.0) | 4 (13.8) | 0.199 |
| mTORi, n (%) | 22 (55.0) | 7 (24.1) | 0.021 |
| CNI, n (%) | 14 (35.0) | 12 (41.4) | 0.773 |
| Steroid ≧ 10mg*, n (%) | 5 (12.5) | 2 (6.9) | 0.69 |
| Dynamic steroid+mTORi, n (%) | 7 (17.5) | 1 (3.4) | 0.125 |
| ICI target, n (%) | 0.101 | ||
| PD-1 | 28 (70.0) | 22 (75.9) | |
| PD-L1 | 6 (15.0) | 0 (0.0) | |
| CTLA-4 | 1 (2.5) | 1 (3.4) | |
| Combination | 5 (12.5) | 6 (20.7) | |
| Nephrotoxin, n (%) | 0.306 | ||
| None | 22 (55.0) | 21 (72.4) | |
| NSAIDs | 1 (2.5) | 0 (0.0) | |
| PPI | 9 (22.5) | 6 (20.7) | |
| Antibiotics | 8 (20.0) | 2 (6.9) | |
| Tumor response, n (%) | 0.992 | ||
| CR | 3 (7.5) | 2 (6.9) | |
| PR | 9 (22.5) | 6 (20.7) | |
| SD | 7 (17.5) | 4 (13.8) | |
| PD | 19 (47.5) | 15 (51.7) | |
| Unknown | 2 (5.0) | 2 (6.9) | |
| Objective response rate [CR+PR], n (%) | 12 (30.0) | 8 (27.6) | 1 |
| Extra renal irAE, n (%) | 9 (22.5) | 8 (27.6) | 0.778 |
| Transplant to ICI, yr | 9 (4.8–14.3) | 9 (4–16) | 0.808 |
Data are shown as median (IQR) and n (%).
prednisone equivalent.
LUKTx; living-unrelated kidney transplant, LRKTx; living-related kidney transplant, DDKTx; deceased kidney transplant, DSA; donor-specific antibody at the time of transplant, cSCC; cutaneous squamous cell carcinoma, NSCLC; non-small cell lung carcinoma, RCC; renal cell carcinoma, mTORi; mammalian target of rapamycin inhibitor, CNI; calcineurin inhibitor, ICI; immune checkpoint inhibitor, PD-1; programmed cell death protein 1, PD-L1; programmed death ligand 1, CTLA-4; cytotoxic T-lymphocyte-associated protein 4, NSAIDs; nonsteroidal anti-inflammatory drugs, PPI; proton pump inhibitor, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease, irAE; immune-related adverse event